Ask AI
ProCE Banner Activity

From Subtle Signs to Serious Impact: Tardive Dyskinesia Nuances in Geriatrics

Slideset

Older adults are at increased risk for tardive dyskinesia (TD), but symptoms may be overlooked amid cognitive impairment, polypharmacy, mobility limitations, and other comorbidities common in geriatric care. This downloadable slideset examines practical strategies for recognizing and assessing TD across primary care, long-term care, and community settings, including structured screening with AIMS and differentiation from other movement disorders. Learners will also review evidence-based management approaches, including individualized use of FDA-approved VMAT2 inhibitors and considerations specific to older adults.

Released: September 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences.

Neurocrine Biosciences

Target Audience

This educational activity is intended for psychiatrists, geriatricians, neurologists, nurse practitioners, physician associates, general and family practice physicians, long-term care pharmacists, psychologists, social workers, and other healthcare professionals who treat patients or advise HCP care teams regarding their patients with tardive dyskinesia who may benefit from this education. Target audiences for specific satellite symposia are adjusted as appropriate for each conference.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply evidence-based strategies to identify, monitor, and counsel older adults at risk for tardive dyskinesia, using validated screening and assessment tools across diverse care settings

  • Integrate structured TD assessment and monitoring protocols into gerontological clinical workflows — including primary care, long term care, and community-based environments — to support early detection and ongoing evaluation

  • Evaluate and implement individualized, evidence-based TD treatment plans, including the appropriate use of FDA approved VMAT2 inhibitors, considering geriatric specific factors such as polypharmacy, cognitive status, and functional needs